Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CNSX:ATT NASDAQ:PCT BATS:PSH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATTAbattis BioceuticalsC$0.00C$0.05▼C$0.74N/AN/A1.42 million shsN/APCTPureCycle Technologies$9.53+6.6%$6.30$4.93▼$17.37$1.62B2.313.65 million shs5.06 million shsPSHPGIM Short Duration High Yield ETF$50.10+0.1%$50.04$49.44▼$51.51$50.10M0.1921,719 shs10,814 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATTAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%PCTPureCycle Technologies0.00%+19.52%+61.96%-7.36%+36.28%PSHPGIM Short Duration High Yield ETF0.00%-0.06%+0.08%-0.67%+0.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATTAbattis BioceuticalsC$0.00C$0.05▼C$0.74N/AN/A1.42 million shsN/APCTPureCycle Technologies$9.53+6.6%$6.30$4.93▼$17.37$1.62B2.313.65 million shs5.06 million shsPSHPGIM Short Duration High Yield ETF$50.10+0.1%$50.04$49.44▼$51.51$50.10M0.1921,719 shs10,814 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATTAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%PCTPureCycle Technologies0.00%+19.52%+61.96%-7.36%+36.28%PSHPGIM Short Duration High Yield ETF0.00%-0.06%+0.08%-0.67%+0.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATTAbattis Bioceuticals 0.00N/AN/AN/APCTPureCycle Technologies 2.50Moderate Buy$12.0025.92% UpsidePSHPGIM Short Duration High Yield ETF 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ATT, SDR, PSH, and PCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026PCTPureCycle Technologies TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$7.00 ➝ $6.002/27/2026PCTPureCycle Technologies Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$16.00 ➝ $14.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATTAbattis BioceuticalsN/AN/AN/AN/AN/AN/APCTPureCycle Technologies$10.90M157.98N/AN/A$0.25 per share38.12PSHPGIM Short Duration High Yield ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATTAbattis BioceuticalsN/AN/AN/AN/AN/AN/AN/AN/AN/APCTPureCycle Technologies-$182.57M-$1.47N/AN/AN/A-2,062.36%-305.03%-21.99%N/APSHPGIM Short Duration High Yield ETFN/AN/AN/AN/AN/AN/AN/AN/AN/ALatest ATT, SDR, PSH, and PCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026PCTPureCycle Technologies-$0.26-$0.21+$0.05-$0.21$3.83 million$4.13 million2/26/2026Q4 2025PCTPureCycle Technologies-$0.25-$0.42-$0.17-$0.14$6.37 million$2.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATTAbattis BioceuticalsN/AN/AN/AN/AN/APCTPureCycle TechnologiesN/AN/AN/AN/AN/APSHPGIM Short Duration High Yield ETF$3.757.49%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATTAbattis BioceuticalsN/AN/AN/APCTPureCycle Technologies7.622.262.15PSHPGIM Short Duration High Yield ETFN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATTAbattis BioceuticalsN/APCTPureCycle Technologies63.01%PSHPGIM Short Duration High Yield ETFN/AInsider OwnershipCompanyInsider OwnershipATTAbattis BioceuticalsN/APCTPureCycle Technologies18.80%PSHPGIM Short Duration High Yield ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATTAbattis BioceuticalsN/AN/AN/ANot OptionablePCTPureCycle Technologies120180.73 million146.75 millionNot OptionablePSHPGIM Short Duration High Yield ETFN/A1.00 millionN/AN/AATT, SDR, PSH, and PCT HeadlinesRecent News About These CompaniesPershing Square Holdings, Ltd. (“PSHâ€) Notes the Closing of Initial Public Offering of Pershing Square USA, Ltd.April 30, 2026 | businesswire.comPershing Square USA opens 16% below IPO price on NYSE debutApril 29, 2026 | proactiveinvestors.comPershing Square Holdings, Ltd. Announces 2026 Dividend ScheduleJanuary 26, 2026 | businesswire.comPershing Square Holdings Ltd. Releases 2025 Semiannual Financial StatementsAugust 20, 2025 | businesswire.comPershing Square Holdings, Ltd. Announces Appointment of Independent Non-Executive DirectorAugust 5, 2025 | businesswire.comPershing Square Holdings, Ltd. Confirms Third Quarter 2025 Dividend for ShareholdersAugust 5, 2025 | businesswire.comPershing Square Holdings, Ltd. Announces Third Quarter 2024 Investor CallNovember 7, 2024 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesPepsiCo Stock Reversal Points Toward New All-Time HighsBy Thomas Hughes | April 16, 202695% Options Surge: Smart Money Bets Big on a Super Micro Bounce By Jeffrey Neal Johnson | April 15, 2026JPMorgan Stock Is Coiling Near All-Time Highs — Here's What Comes NextBy Thomas Hughes | April 14, 2026Why Lockheed Martin's Earnings Miss Could Be a Blessing in DisguiseBy Sam Quirke | May 4, 2026Apple’s Earnings Make $300 Look Like a Matter of When, Not IfBy Sam Quirke | May 1, 2026ATT, SDR, PSH, and PCT Company DescriptionsAbattis Bioceuticals CNSX:ATTAbattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.PureCycle Technologies NASDAQ:PCT$9.53 +0.59 (+6.60%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$9.52 0.00 (-0.05%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PureCycle Technologies, Inc. engages in the production of recycled polypropylene (PP). The company holds a license for restoring waste PP into ultra-pure recycled polypropylene resin that has multiple applications, including packaging and labeling for consumer products, piping, ropes, cabling, and plastic parts for various industries. Its recycling process separates color, odor, and other contaminants from plastic waste feedstock to transform it into virgin-like resin. The company was founded in 2015 and is headquartered in Orlando, Florida.PGIM Short Duration High Yield ETF BATS:PSH$50.10 +0.05 (+0.10%) As of 05/8/2026 04:10 PM EasternThe PGIM Short Duration HIgh Yield ETF (PSH) is an exchange-traded fund that mostly invests in high yield fixed income. The fund is actively managed, investing in a broad portfolio of global fixed income securities that are rated below investment grade. The fund aims to maintain an average portfolio duration of three years or less PSH was launched on Dec 14, 2023 and is issued by PGIM. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
